- Home
- MNOV vs CTOR Comparison
MNOV vs CTOR Comparison
Compare MNOV & CTOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNOV
- CTOR
- Stock Information
- Founded
- MNOV 2000
- CTOR 2021
- Country
- MNOV United States
- CTOR United States
- Employees
- MNOV N/A
- CTOR N/A
- Industry
- MNOV Biotechnology: Pharmaceutical Preparations
- CTOR
- Sector
- MNOV Health Care
- CTOR
- Exchange
- MNOV Nasdaq
- CTOR NYSE
- Market Cap
- MNOV 91.7M
- CTOR 89.9M
- IPO Year
- MNOV 2005
- CTOR N/A
- Fundamental
- Price
- MNOV $1.84
- CTOR $1.23
- Analyst Decision
- MNOV Strong Buy
- CTOR Strong Buy
- Analyst Count
- MNOV 1
- CTOR 2
- Target Price
- MNOV $9.00
- CTOR $4.50
- AVG Volume (30 Days)
- MNOV 20.1K
- CTOR 78.9K
- Earning Date
- MNOV 02-18-2025
- CTOR 02-21-2025
- Dividend Yield
- MNOV N/A
- CTOR N/A
- EPS Growth
- MNOV N/A
- CTOR N/A
- EPS
- MNOV N/A
- CTOR N/A
- Revenue
- MNOV N/A
- CTOR N/A
- Revenue This Year
- MNOV N/A
- CTOR N/A
- Revenue Next Year
- MNOV N/A
- CTOR N/A
- P/E Ratio
- MNOV N/A
- CTOR N/A
- Revenue Growth
- MNOV N/A
- CTOR N/A
- 52 Week Low
- MNOV $1.12
- CTOR $0.85
- 52 Week High
- MNOV $2.55
- CTOR $49.00
- Technical
- Relative Strength Index (RSI)
- MNOV 39.12
- CTOR N/A
- Support Level
- MNOV $1.83
- CTOR N/A
- Resistance Level
- MNOV $1.97
- CTOR N/A
- Average True Range (ATR)
- MNOV 0.07
- CTOR 0.00
- MACD
- MNOV -0.01
- CTOR 0.00
- Stochastic Oscillator
- MNOV 8.33
- CTOR 0.00
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.
About CTOR CITIUS ONCOLOGY INC
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.